Table 1 Model Parameters: Key Clinical and Health Preference Data

Clinical data

Weibull survival model for OS of olaparib plus bevacizumab

Overall patients

Patients with a tumor BRCA mutation

Patients with HRD tumors

Patients with HRD tumors without a BRCA mutation

Scale = 0.0032233, Shape = 1.3412093

Scale = 0.0008312, Shape = 1.4656368

Scale = 0.0013868, Shape = 1.4043253

Scale = 0.0017414, Shape = 1.4345009

-

-

-

-

-

-

-

-

(15)

-

-

-

-

Weibull survival model for PFS of olaparib plus bevacizumab

Overall patients

Patients with a tumor BRCA mutation

Patients with HRD tumors

Patients with HRD tumors without a BRCA mutation

Scale = 0.03432, Shape = 0.900619

Scale = 0.005312, Shape = 1.20865

Scale = 0.014599, Shape = 0.014599

Scale = 0.025081, Shape = 0.913035

-

-

-

-

-

-

-

-

(16)

-

-

-

-

Weibull survival model for OS of bevacizumab

Overall patients

Patients with a tumor BRCA mutation

Patients with HRD tumors

Patients with HRD tumors without a BRCA mutation

Scale = 0.0025282, Shape = 1.427602

Scale = 0.0016336, Shape = 1.4217268

Scale = 0.0014855, Shape = 1.500712

Scale = 0.0009159, Shape = 1.6748696

-

-

-

-

-

-

-

-

(15)

-

-

-

-

Weibull survival model for PFS of bevacizumab

Overall patients

Patients with a tumor BRCA mutation

Patients with HRD tumors

Patients with HRD tumors without a BRCA mutation

Scale = 0.041625, Shape = 0.984316

Scale = 0.022464, Shape = 1.082455

Scale = 0.021614, Shape = 0.021614

Scale = 0.033704, Shape = 0.913035

-

-

-

-

-

-

-

-

(16)

-

-

-

-

Risk for main AEs in olaparib plus bevacizumab group

Risk of fatigue

0.050

0.040

0.060

(15, 16)

Beta

Risk of neutropenia

0.060

0.048

0.072

(15, 16)

Beta

Risk of lymphopenia

0.070

0.056

0.084

(15, 16)

Beta

Risk of anemia

0.170

0.136

0.204

(15, 16)

Beta

Risk of hypertension

0.190

0.152

0.228

(15, 16)

Beta

Risk for main AEs in bevacizumab group

Risk of hypertension

0.300

0.240

0.360

(15, 16)

Beta

Proportion of receiving active second-line treatment

Olaparib plus bevacizumab

0.484

0.387

0.581

(21)

Beta

Bevacizumab

0.610

0.488

0.732

(21)

Beta

Utility and disutility

Utility of PFS

0.840

0.672

1.008

(25, 26)

Beta

Utility of PD

0.790

0.632

0.948

(25, 26)

Beta

Disutility of leukopenia

0.090

0.072

0.108

(23)

Beta

Disutility of fatigue

0.170

0.136

0.204

(24)

Beta

Disutility of neutropenia

0

-

-

(24)

-

Disutility of anemia

0

-

-

(24)

-

Disutility of hypertension

0

-

-

(24)

-

Body weight (kilogram)

70

56

84

(19, 20)

Normal

Body surface area (meters²)

1.84

1.47

2.21

(19, 20)

Normal

Discount rate

0.03

0

0.05

(24)

Uniform